Akorn Inc., together with its subsidiaries, is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health. The Prescription Pharmaceuticals segment is engaged in manufacturing and marketing generic and branded prescription pharmaceuticals, including ophthalmics, injectables, oral liquids, otics, topical, inhalants and nasal sprays. The Consumer Health segment is engaged in manufacturing and marketing branded and private-label animal health and OTC products. The Company's Akorn Consumer Health division (ACH) markets a portfolio of OTC brands and various formulations of private-label OTC pharmaceutical products. Its OTC brand is TheraTears Therapy for Your Eyes, which is a family of therapeutic eye care products.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: Pharmaceuticals
- Exchange: NASDAQ
- Symbol: AKRX
- CUSIP: 00972810
- Previous Close: $21.58
- 50 Day Moving Average: $20.85
- 200 Day Moving Average: $23.91
- 52-Week Range: $125,240,000.00 - $17.57
- Trailing P/E Ratio: 14.40
- Foreward P/E Ratio: 9.81
- P/E Growth: 1.93
- Market Cap: $2.67B
- Outstanding Shares: 125,240,000
- Beta: 1.12
- Net Margins: 16.58%
- Return on Equity: 38.59%
- Return on Assets: 14.15%
Companies Related to Akorn:
- Debt-to-Equity Ratio: 1.00%
- Current Ratio: 4.14%
- Quick Ratio: 2.99%
What is Akorn's stock symbol?
Akorn trades on the NASDAQ under the ticker symbol "AKRX."
Where is Akorn's stock going? Where will Akorn's stock price be in 2017?
17 equities research analysts have issued 12-month target prices for Akorn's stock. Their forecasts range from $20.00 to $45.00. On average, they expect Akorn's share price to reach $29.70 in the next twelve months.
When will Akorn announce their earnings?
Akorn is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.
Who owns Akorn stock?
Akorn's stock is owned by many different of retail and institutional investors. Top institutional investors include Paulson & CO. Inc. (6.94%), William Blair Investment Management LLC (3.32%), State Street Corp (2.39%), FMR LLC (1.85%), Janus Capital Management LLC (1.80%) and Fiera Capital Corp (0.95%). Company insiders that own Akorn stock include Alan D Weinstein, Bruce Kutinsky, John N Kapoor, Joseph Bonaccorsi, Kenneth Abramowitz, Mark M Silverberg, Rajat Rai and Ronald M Johnson.
Who sold Akorn stock? Who is selling Akorn stock?
Akorn's stock was sold by a variety of institutional investors in the last quarter, including Fiera Capital Corp, Folger Hill Asset Management LP, FMR LLC, Clough Capital Partners L P, State Street Corp, Oxford Asset Management, Allianz Asset Management AG and Loomis Sayles & Co. L P. Company insiders that have sold Akorn stock in the last year include Alan D Weinstein, Bruce Kutinsky, Joseph Bonaccorsi, Kenneth Abramowitz and Ronald M Johnson.
Who bought Akorn stock? Who is buying Akorn stock?
Akorn's stock was acquired by a variety of institutional investors in the last quarter, including Paulson & CO. Inc., William Blair Investment Management LLC, Russell Investments Group Ltd., Janus Capital Management LLC, Federated Investors Inc. PA, Dimensional Fund Advisors LP, Gabelli Funds LLC and Columbia Wanger Asset Management LLC. Company insiders that have bought Akorn stock in the last two years include John N Kapoor and Rajat Rai.
How do I buy Akorn stock?
Shares of Akorn can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Akorn stock cost?
One share of Akorn stock can currently be purchased for approximately $21.28.